|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.710 NZD | +0.27% |
|
+0.82% | +9.76% |
| 07:16pm | AFT Pharmaceuticals On Track to Achieve Fiscal 2027 Revenue Target; Iron Injectable Product Clears Regulatory Hurdles | MT |
| 06-23 | NZX Biggest Gainers | MT |
| Market Cap | 389M 222M 194M 179M 165M 315M 21.16B 319M 2.2B 831M 10.39B 833M 815M 35.95B | P/E 2027 * |
19.7x | P/E 2028 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise Value | 419M 239M 209M 192M 178M 339M 22.78B 343M 2.37B 895M 11.19B 897M 877M 38.71B | EV / Sales 2027 * |
1.38x | EV / Sales 2028 * | 1.2x |
| Free-Float |
22.37% | Yield 2027 * |
0.88% | Yield 2028 * | 1.12% |
Last Transcript: AFT Pharmaceuticals Limited
| 24-01-20 | Rentevrees zet Bel20 onder druk | |
| 24-01-19 | KBC uitblinker op groene beurs | |
| 24-01-19 | Brusselse beurs opent flink hoger | |
| 24-01-19 | Brussel start handelsdag vermoedelijk in het groen | |
| 24-01-18 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | +0.27% | ||
| 1 week | +0.82% | ||
| Current month | +1.37% | ||
| 1 month | -5.12% | ||
| 3 months | +10.42% | ||
| 6 months | +9.76% | ||
| Current year | +9.76% |
| 1 week | 3.66 |  | 3.77 |
| 1 month | 3.65 | | 3.97 |
| Current year | 3.35 | | 3.98 |
| 1 year | 2.54 | | 3.98 |
| 3 years | 2.37 | | 3.98 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 2012-09-03 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 1997-09-03 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 2026-06-14 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 2015-06-21 |
Hartley Atkinson
BRD | Director/Board Member | - | 1997-09-03 |
Marree Atkinson
BRD | Director/Board Member | - | 2012-09-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-07-02 | Buy | Founder | 200,000 | 0.1907% | ||
| 25-06-25 | Free | Founder | 17,755 | 0.0169% | ||
| 24-12-01 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.27% | +0.82% | +35.90% | +1.37% | 221M | |
| -1.14% | -0.67% | +53.72% | +157.69% | 1,082B | |
| -1.41% | +1.83% | +66.23% | +59.28% | 633B | |
| -2.42% | +0.56% | +34.59% | +85.12% | 461B | |
| -0.26% | +1.37% | +31.00% | +23.05% | 338B | |
| -2.46% | -1.52% | +36.42% | +32.77% | 299B | |
| -2.20% | -0.93% | +27.50% | +40.62% | 291B | |
| -1.77% | +0.99% | -28.85% | -41.41% | 222B | |
| -2.06% | +2.26% | +22.87% | +62.23% | 202B | |
| -1.26% | +1.35% | +15.98% | +67.80% | 163B | |
| Average | -0.32% | +4.15% | +29.54% | +48.85% | 369.26B | |
| Weighted average by Cap. | +0.05% | +5.43% | +39.61% | +78.91% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 173M 151M 139M 129M 246M 16.53B 249M 1.72B 649M 8.12B 651M 636M 28.08B | 345M 197M 172M 159M 147M 280M 18.78B 283M 1.95B 738M 9.23B 739M 723M 31.91B |
| Net income | 19.71M 11.24M 9.81M 9.05M 8.38M 15.96M 1.07B 16.15M 111M 42.09M 527M 42.2M 41.28M 1.82B | 24.84M 14.16M 12.36M 11.4M 10.56M 20.12M 1.35B 20.35M 140M 53.05M 664M 53.18M 52.02M 2.3B |
| Net Debt | 29.84M 17.01M 14.85M 13.7M 12.69M 24.17M 1.62B 24.44M 169M 63.73M 797M 63.89M 62.49M 2.76B | 24.59M 14.02M 12.24M 11.29M 10.46M 19.92M 1.34B 20.14M 139M 52.51M 657M 52.65M 51.5M 2.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-06 | NZ$3.710 | +0.27% | 10,511 |
| 26-07-03 | NZ$3.700 | +0.82% | 3,160 |
| 26-07-02 | NZ$3.670 | +0.27% | 17,558 |
| 26-07-01 | NZ$3.660 | 0.00% | 441 |
| 26-06-30 | NZ$3.660 | -1.08% | 8,406 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
